CLLS logo

Cellectis SA (CLLS) Company Overview

Profile

Full Name:

Cellectis S.A.

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

March 24, 2015

Indexes:

Not included

Description:

Cellectis SA is a biotechnology company focused on developing innovative gene-editing therapies. They use their proprietary technology to create treatments for various diseases, particularly cancer. Cellectis aims to improve patient outcomes by harnessing the power of the immune system to target and destroy cancer cells.

Key Details

Price

$1.57

Annual Revenue

$755.00 K(-96.06% YoY)

Annual EPS

-$1.77(+24.03% YoY)

Annual ROE

-95.96%

Beta

1.13

Events Calendar

Earnings

Next earnings date:

Apr 29, 2025

Recent quarterly earnings:

Nov 4, 2024

Recent annual earnings:

Apr 29, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Nov 5, 24 Barclays
Overweight
Jun 12, 24 Oppenheimer
Outperform
May 31, 24 JMP Securities
Market Outperform
Nov 1, 23 JMP Securities
Market Outperform
Aug 8, 23 Oppenheimer
Outperform
Aug 7, 23 JMP Securities
Market Outperform
Apr 5, 23 Citigroup
Buy
Mar 13, 23 Oppenheimer
Outperform
Mar 13, 23 JMP Securities
Market Outperform
Jan 19, 23 JMP Securities
Market Outperform

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Cellectis: Poised To Start Answering Questions In 2025
Cellectis: Poised To Start Answering Questions In 2025
Cellectis: Poised To Start Answering Questions In 2025
CLLS
seekingalpha.comDecember 12, 2024

Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a risk to its longevity. Key data updates are coming in 2025 that will give us a look at their lead program in a larger population.

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
CLLS
globenewswire.comDecember 10, 2024

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million (“Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the “EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22.

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
CLLS
globenewswire.comNovember 5, 2024

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that pre-clinical data to enhance CAR T cell activity against solid tumors while preventing potential toxicity, will be presented at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC), that will take place on November 6-10, 2024 in Houston, Texas.

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
CLLS
seekingalpha.comNovember 5, 2024

Cellectis S.A. (NASDAQ:CLLS ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Arthur Stril - Interim Chief Financial Officer Andre Choulika - Chief Executive Officer Adrian Kilcoyne - Chief Medical Officer Conference Call Participants Gena Wang - Barclays Jack Allen - Baird Ashiq Mubarack - Citi Kuan-Hung Lin - Wells Fargo Luisa Morgado - Van Lanschot Kempen Silvan Tuerkcan - Citizens JMP Operator Good morning, everyone, and welcome to the Cellectis Third Quarter 2024 Earnings Call.

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
CLLS
globenewswire.comNovember 4, 2024

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the nine-month period ending September 30, 2024.

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
CLLS
globenewswire.comOctober 30, 2024

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2024 ending September 30, 2024 on Monday, November 4, 2024 after the close of the US market.

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
CLLS
globenewswire.comOctober 22, 2024

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that they will be showcasing pre-clinical data that permit the design of an efficient and specific TALE base editors (TALEB) as well as a process to enhance the efficacy of non-viral gene insertion in hematopoietic stem and progenitor cells (HSPCs) at the European Society of Cell and Gene Therapy 31st annual congress, that will take place on October 22-25, 2024, in Roma, Italy.

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
CLLS
globenewswire.comSeptember 3, 2024

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment option for advance-stage triple negative breast cancer (TNBC) patients with limited therapeutic options.

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
CLLS
globenewswire.comAugust 26, 2024

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published an article in Molecular Therapy demonstrating TALEN®-mediated gene editing capabilities for design of SMART DUAL CAR T-cells, which efficiently target immunotherapy recalcitrant solid tumors while mitigating potential safety risks.

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
CLLS
globenewswire.comAugust 7, 2024

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the appointment of Dr. Adrian Kilcoyne, M.D., MPH, MBA as its Chief Medical Officer, effective immediately.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Cellectis SA?
  • Does Cellectis SA pay dividends?
  • What sector is Cellectis SA in?
  • What industry is Cellectis SA in?
  • What country is Cellectis SA based in?
  • When did Cellectis SA go public?
  • Is Cellectis SA in the S&P 500?
  • Is Cellectis SA in the NASDAQ 100?
  • Is Cellectis SA in the Dow Jones?
  • When was Cellectis SA's last earnings report?
  • When does Cellectis SA report earnings?
  • Should I buy Cellectis SA stock now?

What is the ticker symbol for Cellectis SA?

The ticker symbol for Cellectis SA is NASDAQ:CLLS

Does Cellectis SA pay dividends?

No, Cellectis SA does not pay dividends

What sector is Cellectis SA in?

Cellectis SA is in the Healthcare sector

What industry is Cellectis SA in?

Cellectis SA is in the Biotechnology industry

What country is Cellectis SA based in?

Cellectis SA is headquartered in France

When did Cellectis SA go public?

Cellectis SA's initial public offering (IPO) was on March 24, 2015

Is Cellectis SA in the S&P 500?

No, Cellectis SA is not included in the S&P 500 index

Is Cellectis SA in the NASDAQ 100?

No, Cellectis SA is not included in the NASDAQ 100 index

Is Cellectis SA in the Dow Jones?

No, Cellectis SA is not included in the Dow Jones index

When was Cellectis SA's last earnings report?

Cellectis SA's most recent earnings report was on Nov 4, 2024

When does Cellectis SA report earnings?

The next expected earnings date for Cellectis SA is Apr 29, 2025

Should I buy Cellectis SA stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions